Using an in vivo murine xenografted mouse model, Roccaro et al. [42, 43] demonstrated that CXCR4 blockade by the monoclonal antibody Ulocuplumab, as well as neutralization of SDF-1 by Olaptesed-pegol (PEGylated mirror-image l-oligonucleotide) inhibits MM bone-to-bone cell dissemination and hence tumor progression. The gene discussed is CXCL12; the disease is Miyoshi myopathy.